Valneva SE
VALN evidence brief
What we can confirm
- Market Cap:
- $631.5M
What it means
What to watch
Prepared research question
What matters most for VALN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VALN
Valneva SE is a French specialty vaccine company focused on developing and commercializing vaccines for infectious diseases, with a lead Lyme disease vaccine candidate in late-stage development.
Key risk: Lyme vaccine regulatory approval
Market Cap
$631.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 395 clinical trials for Valneva SE.
Valneva SE is a French specialty vaccine company focused on developing and commercializing vaccines for infectious diseases, with a lead Lyme disease vaccine candidate in late-stage development.
- Total revenues of €174.7 million for full year 2025, including €157.9 million in product sales [news · published 2026-03-18]
- Cash position of €105.3 million as of end March 2026 [news · published 2026-05-13]
- Phase 3 VALOR trial of Lyme disease vaccine candidate PF-07307405 demonstrated strong efficacy [news · published 2026-03-23]
- EMA validated the Marketing Authorization Application for the Lyme disease vaccine candidate in August 2026 [news · published 2026-08-14]
- Debt refinancing completed and a 21% reduction in operating cash burn reported for 2025 [news · published 2026-03-18]
What works
- Strong year-end cash position of €109.7 million as of 2025 year-end, providing financial flexibility [news · published 2026-03-18]
- Lyme disease vaccine candidate achieved positive Phase 3 efficacy results, with MAA validated by EMA [news · published 2026-08-14]
- Successful debt refinancing and reduced operating cash burn (21% in 2025) improved financial stability [news · published 2026-03-18]
What to weigh
- First half 2026 showed a significant operating loss despite strong cash position [news · published 2026-08-13]
- First quarter 2026 product sales of €30.5 million were relatively modest [news · published 2026-05-13]
- Company launched a program in April 2026 to further reduce operating expenses, indicating ongoing cost pressures [news · published 2026-05-13]
From the filings
Quoted directly from source documents.
Lyme disease vaccine candidate demonstrated strong efficacy in Phase 3 VALOR trial
“Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial”
News · March 23, 2026
EMA validated the Marketing Authorization Application for the Lyme disease vaccine candidate
“the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405”
News · August 14, 2026
Full year 2025 total revenues of €174.7 million
“Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales”
News · March 18, 2026
Cash position of €105.3 million as of end March 2026
“Cash position of €105.3 million as of end March 2026”
News · May 13, 2026
Risks & what to watch (3)›
Key risks
- Lyme vaccine regulatory approval — MAA validated but EMA assessment ongoing; approval not guaranteed and timeline uncertain [news · published 2026-08-14]
- Operating losses persist — First half 2026 reported significant operating loss despite strong cash position [news · published 2026-08-13]
- Dependence on Lyme vaccine — Company's near-term outlook heavily tied to success of single lead candidate PF-07307405 [news · published 2026-03-23]
What to watch
- EMA assessment outcome for Lyme disease vaccine MAA, expected in coming months [news · published 2026-08-14]
- Full year 2026 financial results and progress on operating expense reduction program [news · published 2026-05-13]
- Potential FDA filing or updates for Lyme disease vaccine candidate in the US [news · published 2026-05-13]
Sources: Catalysts · News · Generated October 6, 2026 · How we verify sources →
Run Valneva SE through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Valneva SE facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 0.2%
- Days to cover
- 1.3
- Shares short
- 152,470
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VALN short interestFrequently asked questions
What is the AI investment thesis for Valneva SE?
Valneva SE is a French specialty vaccine company focused on developing and commercializing vaccines for infectious diseases, with a lead Lyme disease vaccine candidate in late-stage development.
Who is the CEO of Valneva SE?
Mr. Thomas Lingelbach is the chief executive officer of Valneva SE (VALN).
Where is Valneva SE headquartered?
Valneva SE (VALN) is headquartered in Saint-Herblain, France.
What therapeutic areas does Valneva SE focus on?
Valneva SE develops therapies across Oncology, Rare Disease, Gene Therapy, Neurology, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Nephrology, Musculoskeletal, Gastroenterology, Endocrinology, Reproductive, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.